Anti-angiogenesis Effect of Artesunate Nano-liposomes on Liver Cancer Cell Line HepG2

ZHAO Chun-xia; SHEN Xue-song; JIN Mei-hua; HUANG Li-fang; LIU Han-fu

doi:10.11653/zgsyfjxzz2013070226

您当前的位置：

首页 >

文章列表页 >

Anti-angiogenesis Effect of Artesunate Nano-liposomes on Liver Cancer Cell Line HepG2

更新时间：2024-01-04

- Anti-angiogenesis Effect of Artesunate Nano-liposomes on Liver Cancer Cell Line HepG2
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 19, Issue 7, Pages: 226-229(2013)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.11653/zgsyfjxzz2013070226
  CLC：
- Published：2013
- 稿件说明：
移动端阅览
ZHAO Chun-xia, SHEN Xue-song, JIN Mei-hua, et al. Anti-angiogenesis Effect of Artesunate Nano-liposomes on Liver Cancer Cell Line HepG2[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(7): 226-229.
DOI：

ZHAO Chun-xia, SHEN Xue-song, JIN Mei-hua, et al. Anti-angiogenesis Effect of Artesunate Nano-liposomes on Liver Cancer Cell Line HepG2[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(7): 226-229. DOI： 10.11653/zgsyfjxzz2013070226.

摘要

目的: 探讨在青蒿琥纳米脂质体的干预下

血管内皮生长因子(VEGF)及血管内皮细胞生长因子受体2(VEGFR2)在HepG2中的表达

为肝癌的治疗提供理论依据。方法: 取对数生长期HepG2细胞制成3×105/mL单细胞悬液

接种于35 cm2培养皿中培养24 h后给药

分别设生理盐水对照组、青蒿琥酯原料药组、青蒿琥酯纳米脂质体组(浓度均为μmol·L-1)

药物作用24 h。采用RT-PCR法检测各处理组HepG2细胞中VEGF mRNA及VEGFR2 mRNA的表达水平;Western blotting法检测各处理组HepG2细胞中VEGF及VEGFR2的蛋白表达水平。结果: 青蒿琥酯纳米脂质体组VEGF及VEGFR2 mRNA相对表达量为0.22±0.02

0.09±0.02;对照组为0.55±0.03

0.53±0.02;青蒿琥酯纳米脂质体组VEGF

VEGFR2蛋白相对表达量为0.33±0.06

0.25±0.06

对照组为0.95±0.03

0.78±0.03

(P<0.05)。青蒿琥酯纳米脂质体组与原料药组的VEGF及VEGFR2 mRNA表达和蛋白表达均低于对照组

且纳米脂质体组表达量低于原料药组。结论: 青蒿琥酯纳米脂质体能够抑制肿瘤血管的生成达到抗肿瘤作用

且作用强于青蒿琥酯原料药

有应用于肝癌治疗的潜在价值。

Abstract

Objective: To explore the effect of artesunate nano-liposomes on vascular endothelial growth factor (VEGF) and VEGF receptor expression in HepG2 cells

provide the basic theory for liver cancer treatment. Method: HepG2 cells were cultured in vitro. Expression levels of VEGF mRNA and VEGFR-2 mRNA in HepG2 cells were evaluated in the control group

the artesunate active pharmaceutical ingredient(API) group and the artesunate nano-liposomes group by using RT-PCR method

protein expression levels of VEGF and VEGFR2 in HepG2 cells were detected by Western blotting method. Result: Compared mean values between the three groups

the artesunate nano-liposomes and the artesunate API could decrease the protein expression levels of mRNA and of VEGF and VEGFR2 in HepG2 cells (P<0.05). The expression intensity of the artesunate nano-liposomes group was lower than that of the artesunate API group. Conclusion: Artesunate nano-liposomes could inhibit the formation of new blood vessels

suppress tumor cells and have the potential use for the treatment of liver cancer.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Berbamine Hydrochloride Ameliorates Sorafenib Resistance by Regulating Autophagy and PI3K/Akt/mTOR Signaling Pathway

Intervention Mechanism of Biejiajian Wan on Primary Liver Cancer by Regulating lncRNA SNHG5/miRNA-26a-5p/GSK-3β Signal Axis

Artesunate Combined with Other Medications and Action Mechanism： A Review

Effect of Compound Phyllanthus urinaria Ⅱ on Growth and Expression of miR-122 and IGF-1R of Hepatocellular Carcinoma Hep3B Cells in Nude Mice

Anti-liver Cancer Mechanisms of Biejiajian Wan and Clinical Research： A Review

Related Author

WU Zeming

HUANG Xinhui

PENG Qin

XIAO Ling

HUANG Ziyuan

LIN Yiya

TAN Yuhui

SHAO Fanlei

Related Institution

School of Life Sciences and Technology,Tongji University

Bao'an Traditional Chinese Medicine Hospital Affiliated to Guangzhou University of Chinese Medicine

School of Basic Medical Sciences,Guangzhou University of Chinese Medicine

The First Affiliated Hospital of Henan University of Chinese Medicine

Henan University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰